Skip to content
Clemedi
  • Home
  • Team
  • Tuberculosis
  • Awards
  • News
  • Jobs
  • Twitter
  • Facebook
  • LinkedIn

Category: Blog

Clemedi Update Q4 2022
Jan 16, 2023

Clemedi Update Q4 2022

Dear investors, partners, supporters and friends, we closed the year by increasing our marketing efforts. You might have noticed an increased frequency of linkedIn posts, which we kindly ask you to like and repost. Exhibiting at the MEDICA fair brought in a large number of customer leads which we will be following-up and bring to…

read more
by Sebastian Dümckein Blog0
Press Release
Dec 16, 2022

Press Release

English Version Schlieren, Switzerland, Munich, Germany, and Vienna, Austria, December 16, 2022 Clemedi AG concludes a license agreement for detecting latent tuberculosis with the Max Planck Society (MPG) and the Medical University of Vienna Clemedi aims to extend its tuberculosis product line to cover latent tuberculosis. This requires the ability to extract M. tuberculosis DNA…

read more
by Sebastian Dümckein Blog, Press releases0
Press Release
Oct 31, 2022

Press Release

Clemedi AG releases Tuberculini, its first molecular test for drug-resistant tuberculosis. Tuberculini is optimized to run on Thermo Fisher Scientific’s Ion GeneStudio S5™ System. Clemedi has developed a next-generation sequencing (NGS) based test called Tuberculini, that can recognise resistance to all major therapeutic agents used to treat tuberculosis. The assay – which received a CE-IVD…

read more
by Sebastian Dümckein Blog, Press releases0
Clemedi Update Q3 2022
Oct 7, 2022

Clemedi Update Q3 2022

Dear investors, partners, supporters and friends,during this quarter we started our transition from a research organisation towards a sales organisation. After the successful certification of our tuberculosis product last quarter we are now focussing our efforts on marketing and sales. Fundraising We are actively raising funds to finance our market entry in Europe and India…

read more
by Sebastian Dümckein Blog0
Clemedi Update Q2 2022
Jul 15, 2022

Clemedi Update Q2 2022

Dear investors, partners, supporters and friends,we have reached an important milestone and have brought our first product, Tuberculini, to market as a CE-IVD marked medical device. Product Development We have self-certified our product Tuberculini in Germany. It is intended to genotype M. tuberculosis bacteria found in a sample of patients confirmed with tuberculosis. The product…

read more
by Sebastian Dümckein Blog0
Clemedi Update Q1 2022
Apr 13, 2022

Clemedi Update Q1 2022

Dear investors, partners, supporters and friends,a lot has happened since the year started and in the following update I will briefly inform you of the major developments. Business Development We have secured a commercial use agreement with our largest supplier, ThermoFisherScientific. This will allow us to use components from Thermo inside out IVD Kits whilst…

read more
by Sebastian Dümckein Blog0

Posts navigation

1 2
  • Twitter
  • Facebook
  • LinkedIn
  • Terms and Conditions
  • Privacy Policy
© 2025 Clemedi. All rights reserved.
  • Twitter
  • Facebook
  • LinkedIn
Address:Wagistr. 12, 8952 Schlieren, Switzerland
Phone:+41 (0)43 229 38 21‬